AA
MRNA icon

AlphaMark Advisors’s Moderna MRNA Stock Holding History

AlphaMark Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17
Closed -$2K – 774
2023
Q4 		$2K Sell
17
-50
-75% -$4.21K ﹤0.01% 658
2023
Q3 		$7K Buy
67
+17
+34% +$1.9K ﹤0.01% 557
2023
Q2 		$6K Buy
+50
New +$6.67K ﹤0.01% 468
2023
Q1 		– Sell
-75
Closed -$13K – 643
2022
Q4 		$13K Hold
75
– – 0.01% 342
2022
Q3 		$9K Hold
75
– – ﹤0.01% 431
2022
Q2 		$11K Sell
75
-200
-73% -$28.6K 0.01% 385
2022
Q1 		$47K Sell
275
-140
-34% -$23.6K 0.02% 234
2021
Q4 		$105K Buy
415
+64
+18% +$18.7K 0.04% 184
2021
Q3 		$135K Buy
351
+1
+0.3% +$369 0.05% 164
2021
Q2 		$82K Sell
350
-175
-33% -$31.3K 0.03% 195
2021
Q1 		$69K Sell
525
-220
-30% -$31.9K 0.03% 202
2020
Q4 		$78K Buy
745
+645
+645% +$65.3K 0.03% 180
2020
Q3 		$7K Buy
100
+60
+150% +$4.18K ﹤0.01% 408
2020
Q2 		$3K Buy
+40
New +$2.19K ﹤0.01% 472

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AlphaMark Advisors's MRNA Position: Q1 2024 in Review

AlphaMark Advisors sold out of Moderna (MRNA) in Q1 2024, closing a stake of 17 shares — an estimated $2K sold.

AlphaMark Advisors first reported a position in MRNA in Q2 2020 and held it in 14 quarters. The position peaked at $135K in Q3 2021. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • AlphaMark Advisors reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • AlphaMark Advisors sold 17 Moderna shares in Q1 2024, an estimated $2K.
  • AlphaMark Advisors first reported a position in Moderna in Q2 2020 and held it in 14 quarters.
  • AlphaMark Advisors's Moderna position peaked at $135K in Q3 2021.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on AlphaMark Advisors's 13F filing for Q1 2024, filed 18 Apr 2024.